Antibody (Ab) Responses Determined by a Varicella Zoster Virus Glycoprotein–Based Enzyme-Linked Immunosorbent Assay
| End Point, Time . | Group 1 . | Group 2 . | Group 3 . | Group 4 . | ||||
|---|---|---|---|---|---|---|---|---|
| Participants, No. . | Ab Level, U/mL (95% CI) . | Participants, No. . | Ab Level, U/mL (95% CI) . | Participants, No. . | Ab Level, U/mL (95% CI) . | Participants, No. . | Ab Level, U/mL (95% CI) . | |
| GMT | ||||||||
| Day 1 | 201 | 248 (220–280) | 199 | 254 (224–289) | 100 | 212 (174–259) | 98 | 260 (218–310) |
| Week 1 | 200 | 309 (278–344) | 197 | 285 (251–324) | 100 | 298 (251–355) | 96 | 349 (296–410) |
| Week 6 | 198 | 389 (351–431) | 195 | 369 (331–412) | 98 | 403 (345–469) | 97 | 445 (385–514) |
| Week 52 | 182 | 282 (251–316) | 171 | 283 (248–322) | 89 | 271 (226–325) | 91 | 292 (248–343) |
| GMFR | ||||||||
| Week 1 | 200 | 1.2 (1.2–1.3) | 197 | 1.1 (1.1–1.2) | 100 | 1.4 (1.3–1.5) | 96 | 1.4 (1.3–1.5) |
| Week 6 | 198 | 1.5 (1.3–1.6) | 195 | 1.5 (1.4–1.6) | 98 | 1.9 (1.7–2.1) | 97 | 1.7 (1.6–1.9) |
| Week 52 | 182 | 1.1 (1.1–1.2) | 171 | 1.1 (1.0–1.2) | 89 | 1.2 (1.1–1.3) | 91 | 1.2 (1.1–1.3) |
| End Point, Time . | Group 1 . | Group 2 . | Group 3 . | Group 4 . | ||||
|---|---|---|---|---|---|---|---|---|
| Participants, No. . | Ab Level, U/mL (95% CI) . | Participants, No. . | Ab Level, U/mL (95% CI) . | Participants, No. . | Ab Level, U/mL (95% CI) . | Participants, No. . | Ab Level, U/mL (95% CI) . | |
| GMT | ||||||||
| Day 1 | 201 | 248 (220–280) | 199 | 254 (224–289) | 100 | 212 (174–259) | 98 | 260 (218–310) |
| Week 1 | 200 | 309 (278–344) | 197 | 285 (251–324) | 100 | 298 (251–355) | 96 | 349 (296–410) |
| Week 6 | 198 | 389 (351–431) | 195 | 369 (331–412) | 98 | 403 (345–469) | 97 | 445 (385–514) |
| Week 52 | 182 | 282 (251–316) | 171 | 283 (248–322) | 89 | 271 (226–325) | 91 | 292 (248–343) |
| GMFR | ||||||||
| Week 1 | 200 | 1.2 (1.2–1.3) | 197 | 1.1 (1.1–1.2) | 100 | 1.4 (1.3–1.5) | 96 | 1.4 (1.3–1.5) |
| Week 6 | 198 | 1.5 (1.3–1.6) | 195 | 1.5 (1.4–1.6) | 98 | 1.9 (1.7–2.1) | 97 | 1.7 (1.6–1.9) |
| Week 52 | 182 | 1.1 (1.1–1.2) | 171 | 1.1 (1.0–1.2) | 89 | 1.2 (1.1–1.3) | 91 | 1.2 (1.1–1.3) |
Group 1 comprised subjects aged ≥70 years who received zoster vaccine (ZV) ≥10 years previously, group 2 comprised subjects aged ≥70 years who never received ZV and were matched to group 1 subjects by 5-year age increments, group 3 comprised subjects aged ≥60 to <70 years who never received ZV, and group 4 comprised subjects aged ≥50 to <60 years who never received ZV.
Abbreviations: CI, confidence interval; GMFR, geometric mean fold-rise from baseline; GMT, geometric mean titer.
Antibody (Ab) Responses Determined by a Varicella Zoster Virus Glycoprotein–Based Enzyme-Linked Immunosorbent Assay
| End Point, Time . | Group 1 . | Group 2 . | Group 3 . | Group 4 . | ||||
|---|---|---|---|---|---|---|---|---|
| Participants, No. . | Ab Level, U/mL (95% CI) . | Participants, No. . | Ab Level, U/mL (95% CI) . | Participants, No. . | Ab Level, U/mL (95% CI) . | Participants, No. . | Ab Level, U/mL (95% CI) . | |
| GMT | ||||||||
| Day 1 | 201 | 248 (220–280) | 199 | 254 (224–289) | 100 | 212 (174–259) | 98 | 260 (218–310) |
| Week 1 | 200 | 309 (278–344) | 197 | 285 (251–324) | 100 | 298 (251–355) | 96 | 349 (296–410) |
| Week 6 | 198 | 389 (351–431) | 195 | 369 (331–412) | 98 | 403 (345–469) | 97 | 445 (385–514) |
| Week 52 | 182 | 282 (251–316) | 171 | 283 (248–322) | 89 | 271 (226–325) | 91 | 292 (248–343) |
| GMFR | ||||||||
| Week 1 | 200 | 1.2 (1.2–1.3) | 197 | 1.1 (1.1–1.2) | 100 | 1.4 (1.3–1.5) | 96 | 1.4 (1.3–1.5) |
| Week 6 | 198 | 1.5 (1.3–1.6) | 195 | 1.5 (1.4–1.6) | 98 | 1.9 (1.7–2.1) | 97 | 1.7 (1.6–1.9) |
| Week 52 | 182 | 1.1 (1.1–1.2) | 171 | 1.1 (1.0–1.2) | 89 | 1.2 (1.1–1.3) | 91 | 1.2 (1.1–1.3) |
| End Point, Time . | Group 1 . | Group 2 . | Group 3 . | Group 4 . | ||||
|---|---|---|---|---|---|---|---|---|
| Participants, No. . | Ab Level, U/mL (95% CI) . | Participants, No. . | Ab Level, U/mL (95% CI) . | Participants, No. . | Ab Level, U/mL (95% CI) . | Participants, No. . | Ab Level, U/mL (95% CI) . | |
| GMT | ||||||||
| Day 1 | 201 | 248 (220–280) | 199 | 254 (224–289) | 100 | 212 (174–259) | 98 | 260 (218–310) |
| Week 1 | 200 | 309 (278–344) | 197 | 285 (251–324) | 100 | 298 (251–355) | 96 | 349 (296–410) |
| Week 6 | 198 | 389 (351–431) | 195 | 369 (331–412) | 98 | 403 (345–469) | 97 | 445 (385–514) |
| Week 52 | 182 | 282 (251–316) | 171 | 283 (248–322) | 89 | 271 (226–325) | 91 | 292 (248–343) |
| GMFR | ||||||||
| Week 1 | 200 | 1.2 (1.2–1.3) | 197 | 1.1 (1.1–1.2) | 100 | 1.4 (1.3–1.5) | 96 | 1.4 (1.3–1.5) |
| Week 6 | 198 | 1.5 (1.3–1.6) | 195 | 1.5 (1.4–1.6) | 98 | 1.9 (1.7–2.1) | 97 | 1.7 (1.6–1.9) |
| Week 52 | 182 | 1.1 (1.1–1.2) | 171 | 1.1 (1.0–1.2) | 89 | 1.2 (1.1–1.3) | 91 | 1.2 (1.1–1.3) |
Group 1 comprised subjects aged ≥70 years who received zoster vaccine (ZV) ≥10 years previously, group 2 comprised subjects aged ≥70 years who never received ZV and were matched to group 1 subjects by 5-year age increments, group 3 comprised subjects aged ≥60 to <70 years who never received ZV, and group 4 comprised subjects aged ≥50 to <60 years who never received ZV.
Abbreviations: CI, confidence interval; GMFR, geometric mean fold-rise from baseline; GMT, geometric mean titer.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
